Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Systemic and local effects of vaginal dehydroepiandrosterone (DHEA): NCCTG N10C1 (Alliance)

Systemic and local effects of vaginal dehydroepiandrosterone (DHEA): NCCTG N10C1 (Alliance) Background Dehydroepiandrosterone (DHEA) is helpful for evaluable blood and 46 contributed evaluable cytology and treating vaginal symptoms. This secondary analysis evaluated pH values. Circulating DHEA-S and testosterone levels were the impact of vaginal DHEA on hormone concentrations, significantly increased in those on vaginal DHEA in a dose- bone turnover, and vaginal cytology in women with a cancer dependent manner compared to PM. Estradiol was significant- history. ly increased in those on 6.5 mg/day DHEA but not in those on Methods Postmenopausal women, diagnosed with breast or 3.25 mg/day DHEA (p <0.05 and p = 0.05, respectively), and gynecologic cancer, were eligible if they reported at least not in those on AIs. Biomarkers of bone formation were un- moderate vaginal symptoms. Participants could be on tamox- changed in all arms. Maturation of vaginal cells was 100% ifen or aromatase inhibitors (AIs). Women were randomized (3.25 mg/day), 86% (6.5 mg/day), and 64% (PM); pH de- to 3.25 versus 6.5 mg/day of DHEA versus a plain moisturizer creased more in DHEA arms. (PM) control. Sex steroid hormone levels, biomarkers of bone Conclusion DHEA resulted in increased hormone concentra- formation, vaginal pH, and maturation index were collected at tions, though still in the http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Supportive Care in Cancer Springer Journals

Loading next page...
1
 
/lp/springer_journal/systemic-and-local-effects-of-vaginal-dehydroepiandrosterone-dhea-UKAcnwCAq1

References (36)

Publisher
Springer Journals
Copyright
Copyright © 2017 by Springer-Verlag GmbH Germany, part of Springer Nature
Subject
Medicine & Public Health; Oncology; Nursing; Nursing Research; Pain Medicine; Rehabilitation Medicine
ISSN
0941-4355
eISSN
1433-7339
DOI
10.1007/s00520-017-3960-9
Publisher site
See Article on Publisher Site

Abstract

Background Dehydroepiandrosterone (DHEA) is helpful for evaluable blood and 46 contributed evaluable cytology and treating vaginal symptoms. This secondary analysis evaluated pH values. Circulating DHEA-S and testosterone levels were the impact of vaginal DHEA on hormone concentrations, significantly increased in those on vaginal DHEA in a dose- bone turnover, and vaginal cytology in women with a cancer dependent manner compared to PM. Estradiol was significant- history. ly increased in those on 6.5 mg/day DHEA but not in those on Methods Postmenopausal women, diagnosed with breast or 3.25 mg/day DHEA (p <0.05 and p = 0.05, respectively), and gynecologic cancer, were eligible if they reported at least not in those on AIs. Biomarkers of bone formation were un- moderate vaginal symptoms. Participants could be on tamox- changed in all arms. Maturation of vaginal cells was 100% ifen or aromatase inhibitors (AIs). Women were randomized (3.25 mg/day), 86% (6.5 mg/day), and 64% (PM); pH de- to 3.25 versus 6.5 mg/day of DHEA versus a plain moisturizer creased more in DHEA arms. (PM) control. Sex steroid hormone levels, biomarkers of bone Conclusion DHEA resulted in increased hormone concentra- formation, vaginal pH, and maturation index were collected at tions, though still in the

Journal

Supportive Care in CancerSpringer Journals

Published: Nov 21, 2017

There are no references for this article.